Caredx Stock Price, News & Analysis

CareDx, Inc. (Nasdaq: CDNA), a leader in precision medicine for transplant patients, will participate in the Jefferies Healthcare Conference on June 9, 2022, at 2:00 PM ET. The presentation can be accessed via the investor relations section of CareDx's website. CareDx is focused on developing high-value healthcare solutions and offers a range of testing services and products for pre- and post-transplant patients. For more details, visit www.CareDx.com.

CareDx, the Transplant Company™, announced the development of AiKidney, an AI-driven tool for assessing the risk of kidney allograft rejection.

This new addition aims to enhance clinical decision-making alongside existing products like AlloSure. AiKidney predicts rejection risk and allograft survival at three, five, and seven years, aligning with CareDx's mission to improve long-term patient outcomes.

Presentations on these innovations will occur at the upcoming Transplant Congress from June 4-8 in Boston.

CareDx, a leader in precision medicine for transplant patients, showcased its innovations at the 2022 American Transplant Congress with over 50 presentations, including the first oral presentation of the OKRA study. The study involved data from over 50 centers, emphasizing the impact of CareDx’s multimodal KidneyCare solutions, including AlloSure and AlloMap. CEO Reg Seeto highlighted the potential of these technologies in improving patient outcomes. The congress runs from June 4-8 in Boston, Massachusetts.

CareDx Expands Transplant Portfolio in Europe

CareDx, Inc. (CDNA) announced the CE marking for its AlloSeq HCT chimerism testing kit and interpretation software, aimed at improving care for hematopoietic cell transplantation (HCT) patients in Europe. This innovative NGS-based test enhances sensitivity in monitoring engraftment compared to traditional methods. CEO Reg Seeto emphasized the company's commitment to delivering high-quality products. Dr. Jean Villard praised the AlloSeq HCT for its superior sensitivity, which could help predict early disease relapse.

CareDx, Inc. has announced the selection of Dr. Berta Sáez-Giménez for the ISHLT Innovation Challenge Award. Her research will utilize AlloSeq cfDNA to monitor treatment for chronic lung allograft dysfunction (CLAD), critical for improving outcomes in lung transplant patients. With a five-year survival rate around 53%, addressing CLAD is vital as it significantly affects mortality rates. CareDx aims to provide early warnings of organ injury through cfDNA testing, thereby enhancing transplant patient care.

CareDx, Inc. (NASDAQ: CDNA) announces updates in its ongoing patent battle with Natera. Natera has withdrawn a patent but has filed two variations against CareDx, which it believes are invalid and not infringed. This development follows a jury trial in March 2022 where CareDx was awarded $44.9 million for Natera's false advertising related to the Prospera test. CareDx maintains that its donor-derived cell-free DNA technology, AlloSure, is specifically designed for transplant patients.

CareDx, Inc. (CDNA) will present its AlloSeq portfolio at the EFI 2022 Conference from May 17-20 in Amsterdam. The AlloSeq solutions, crucial for HLA typing and post-transplant monitoring, highlight the company's leadership in transplant diagnostics. CEO Reg Seeto emphasized CareDx's unique focus on transplant solutions, which serve as vital tools for researchers and clinicians. The symposium on May 18 will discuss advancements in patient care related to transplantation, showcasing significant collaborations in the field.

CareDx, Inc. (CDNA) reported an 18% year-over-year revenue increase to $79.4 million for Q1 2022, driven by strong performance in testing services, which generated $66.4 million. The company showcased scientific leadership at the International Society of Heart and Lung Transplantation with over 25 presentations and secured $44.9 million in damages against Natera for false claims. Despite revenue growth, CareDx recorded a net loss of $19.6 million and a negative EBITDA of $5.6 million. The company reiterated its full-year 2022 revenue guidance of $330 million to $350 million.

CareDx, Inc. (CDNA) announced new data from the multi-center OKRA study confirming that AlloMap Kidney can predict allograft rejection, specifically antibody-mediated rejection (ABMR) and T cell-mediated rejection (TCMR). With a negative predictive value of 95%, this gene expression profiling can effectively distinguish rejection from quiescence in kidney transplant patients. CEO Reg Seeto noted that these findings advance their KidneyCare solutions. This data aligns with previous studies indicating AlloSure's effectiveness in monitoring renal transplant rejection.